Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Total Liabilities
Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has total liabilities worth CN¥3.71 Billion CNY (≈ $542.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Nanjing King-friend Biochemical Pharmace (603707) asset resilience to evaluate the company's liquid asset resilience ratio.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Douglas Emmett Inc
NYSE:DEI
|
USA | $5.87 Billion |
|
Luenmei Quantum Co Ltd
SHG:600167
|
China | CN¥4.37 Billion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
USA | $150.22 Million |
|
ATS CORP
TO:ATS
|
Canada | CA$2.70 Billion |
|
Scandic Hotels Group AB (publ)
ST:SHOT
|
Sweden | Skr50.29 Billion |
|
Aluar Aluminio Argentino
BA:ALUA
|
Argentina | AR$1.40 Trillion |
|
Ningbo Shuanglin Auto Parts
SHE:300100
|
China | CN¥3.70 Billion |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
China | CN¥2.89 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nanjing King-friend Biochemical Pharmace balance sheet assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total liabilities of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.44 Billion ≈ $503.85 Million |
+13.95% |
| 2024-12-31 | CN¥3.02 Billion ≈ $442.18 Million |
-18.89% |
| 2023-12-31 | CN¥3.73 Billion ≈ $545.20 Million |
-3.05% |
| 2022-12-31 | CN¥3.84 Billion ≈ $562.34 Million |
+36.56% |
| 2021-12-31 | CN¥2.81 Billion ≈ $411.80 Million |
-29.22% |
| 2020-12-31 | CN¥3.98 Billion ≈ $581.78 Million |
+91.67% |
| 2019-12-31 | CN¥2.07 Billion ≈ $303.54 Million |
+111.40% |
| 2018-12-31 | CN¥981.21 Million ≈ $143.58 Million |
+52.72% |
| 2017-12-31 | CN¥642.50 Million ≈ $94.02 Million |
+208.75% |
| 2016-12-31 | CN¥208.09 Million ≈ $30.45 Million |
+1.65% |
| 2015-12-31 | CN¥204.72 Million ≈ $29.96 Million |
-59.72% |
| 2014-12-31 | CN¥508.26 Million ≈ $74.37 Million |
+265.89% |
| 2013-12-31 | CN¥138.91 Million ≈ $20.33 Million |
-- |
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more